Disease management programs

Edward P Armstrong, Paul C. Langley

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Disease management (DM) activities are described, and their implementation and monitoring in managed care organizations are discussed. DM programs involve systematic evaluation of the relationships between treatment options and the associated resource use and patient outcomes for the purpose of providing a given standard of health care at the lowest possible resource cost. A DM arrangement covers a specified disease or therapy intervention for a patient group that may be defined by diagnosis, drug use, prior resource use, or patient characteristics. Often, the partners in a DM arrangement are a managed care organization and a pharmaceutical industry representative or division. The development and monitoring of disease management arrangements are dependent on access to several types of data, and these data are available in managed care plans. A DM arrangement includes interventions to change prescribing patterns or patient compliance and assessment of the effects of these interventions against target outcomes specified in the contract. The agreement that is developed specifies guidelines for treatment and requirements for data collection, monitoring, and reporting that are consistent with the target outcomes. In many DM arrangements, the partners share cost savings and risk; other arrangements involve case management on a capitated basis. A pharmaceutical company involved in risk sharing must change its focus from market share to optimal use of drugs within the total cost of treatment. If a risk-sharing contract covers an entire therapeutic class of drugs, a pharmaceutical company may share risk for the use of other manufacturers' products as well as its own. Disease management contracts must consider the full impact of each treatment option on the health system; the goal should be not simply to decrease the drug budget, but to decrease overall costs for treatment that achieves desired outcomes for specific diseases.

Original languageEnglish (US)
Pages (from-to)53-58
Number of pages6
JournalAmerican Journal of Health-System Pharmacy
Volume53
Issue number1
StatePublished - Jan 1 1996

Fingerprint

Disease Management
Managed Care Programs
Contracts
Pharmaceutical Preparations
Health Care Costs
Organizations
Therapeutics
Cost Savings
Drug Industry
Case Management
Budgets
Standard of Care
Patient Compliance
Research Design
Guidelines
Delivery of Health Care
Costs and Cost Analysis
Health

Keywords

  • Administration
  • Compliance
  • Contracts
  • Costs
  • Diseases
  • Industry, pharmaceutical
  • Managed care systems
  • Patient care
  • Prescribing
  • Protocols

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Leadership and Management

Cite this

Disease management programs. / Armstrong, Edward P; Langley, Paul C.

In: American Journal of Health-System Pharmacy, Vol. 53, No. 1, 01.01.1996, p. 53-58.

Research output: Contribution to journalArticle

Armstrong, Edward P ; Langley, Paul C. / Disease management programs. In: American Journal of Health-System Pharmacy. 1996 ; Vol. 53, No. 1. pp. 53-58.
@article{8e0f8be0d44c488983068398d534b1a1,
title = "Disease management programs",
abstract = "Disease management (DM) activities are described, and their implementation and monitoring in managed care organizations are discussed. DM programs involve systematic evaluation of the relationships between treatment options and the associated resource use and patient outcomes for the purpose of providing a given standard of health care at the lowest possible resource cost. A DM arrangement covers a specified disease or therapy intervention for a patient group that may be defined by diagnosis, drug use, prior resource use, or patient characteristics. Often, the partners in a DM arrangement are a managed care organization and a pharmaceutical industry representative or division. The development and monitoring of disease management arrangements are dependent on access to several types of data, and these data are available in managed care plans. A DM arrangement includes interventions to change prescribing patterns or patient compliance and assessment of the effects of these interventions against target outcomes specified in the contract. The agreement that is developed specifies guidelines for treatment and requirements for data collection, monitoring, and reporting that are consistent with the target outcomes. In many DM arrangements, the partners share cost savings and risk; other arrangements involve case management on a capitated basis. A pharmaceutical company involved in risk sharing must change its focus from market share to optimal use of drugs within the total cost of treatment. If a risk-sharing contract covers an entire therapeutic class of drugs, a pharmaceutical company may share risk for the use of other manufacturers' products as well as its own. Disease management contracts must consider the full impact of each treatment option on the health system; the goal should be not simply to decrease the drug budget, but to decrease overall costs for treatment that achieves desired outcomes for specific diseases.",
keywords = "Administration, Compliance, Contracts, Costs, Diseases, Industry, pharmaceutical, Managed care systems, Patient care, Prescribing, Protocols",
author = "Armstrong, {Edward P} and Langley, {Paul C.}",
year = "1996",
month = "1",
day = "1",
language = "English (US)",
volume = "53",
pages = "53--58",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "1",

}

TY - JOUR

T1 - Disease management programs

AU - Armstrong, Edward P

AU - Langley, Paul C.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Disease management (DM) activities are described, and their implementation and monitoring in managed care organizations are discussed. DM programs involve systematic evaluation of the relationships between treatment options and the associated resource use and patient outcomes for the purpose of providing a given standard of health care at the lowest possible resource cost. A DM arrangement covers a specified disease or therapy intervention for a patient group that may be defined by diagnosis, drug use, prior resource use, or patient characteristics. Often, the partners in a DM arrangement are a managed care organization and a pharmaceutical industry representative or division. The development and monitoring of disease management arrangements are dependent on access to several types of data, and these data are available in managed care plans. A DM arrangement includes interventions to change prescribing patterns or patient compliance and assessment of the effects of these interventions against target outcomes specified in the contract. The agreement that is developed specifies guidelines for treatment and requirements for data collection, monitoring, and reporting that are consistent with the target outcomes. In many DM arrangements, the partners share cost savings and risk; other arrangements involve case management on a capitated basis. A pharmaceutical company involved in risk sharing must change its focus from market share to optimal use of drugs within the total cost of treatment. If a risk-sharing contract covers an entire therapeutic class of drugs, a pharmaceutical company may share risk for the use of other manufacturers' products as well as its own. Disease management contracts must consider the full impact of each treatment option on the health system; the goal should be not simply to decrease the drug budget, but to decrease overall costs for treatment that achieves desired outcomes for specific diseases.

AB - Disease management (DM) activities are described, and their implementation and monitoring in managed care organizations are discussed. DM programs involve systematic evaluation of the relationships between treatment options and the associated resource use and patient outcomes for the purpose of providing a given standard of health care at the lowest possible resource cost. A DM arrangement covers a specified disease or therapy intervention for a patient group that may be defined by diagnosis, drug use, prior resource use, or patient characteristics. Often, the partners in a DM arrangement are a managed care organization and a pharmaceutical industry representative or division. The development and monitoring of disease management arrangements are dependent on access to several types of data, and these data are available in managed care plans. A DM arrangement includes interventions to change prescribing patterns or patient compliance and assessment of the effects of these interventions against target outcomes specified in the contract. The agreement that is developed specifies guidelines for treatment and requirements for data collection, monitoring, and reporting that are consistent with the target outcomes. In many DM arrangements, the partners share cost savings and risk; other arrangements involve case management on a capitated basis. A pharmaceutical company involved in risk sharing must change its focus from market share to optimal use of drugs within the total cost of treatment. If a risk-sharing contract covers an entire therapeutic class of drugs, a pharmaceutical company may share risk for the use of other manufacturers' products as well as its own. Disease management contracts must consider the full impact of each treatment option on the health system; the goal should be not simply to decrease the drug budget, but to decrease overall costs for treatment that achieves desired outcomes for specific diseases.

KW - Administration

KW - Compliance

KW - Contracts

KW - Costs

KW - Diseases

KW - Industry, pharmaceutical

KW - Managed care systems

KW - Patient care

KW - Prescribing

KW - Protocols

UR - http://www.scopus.com/inward/record.url?scp=0030051922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030051922&partnerID=8YFLogxK

M3 - Article

C2 - 8719290

AN - SCOPUS:0030051922

VL - 53

SP - 53

EP - 58

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 1

ER -